RNA polymerase III-driven expression cassettes in human gene

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 5, 1999, Pages 580-594

  Medina, Maria Fe C ^a   Joshi, Sadhna ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adenovirus virus associated RNA; Antisense RNA; Decoy RNA; Polymerase III; Ribozyme; U6 snRNA

Indexed keywords

DNA DIRECTED RNA POLYMERASE III; RIBOZYME; RNA; VIRUS RNA;

ENZYME ACTIVITY; ENZYME ANALYSIS; GENE CASSETTE; GENE TARGETING; GENE THERAPY; HUMAN; PROTEIN EXPRESSION; PROTEIN STABILITY; REVIEW; RNA ANALYSIS;

GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; RNA; RNA POLYMERASE III; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; RNA, CATALYTIC; TERMINATOR REGIONS (GENETICS);

EID: 0032692170     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Willis IM: RNA polymerase III. Genes, factors and transcriptional specificity. Eur J Biochem (1993) 212:1-11.
2. Geiduschek EP, Tocchini-Valentini GP: Transcription by RNA polymerase III. Annu Rev Biochem (1988) 57:873-914.
3. Kunkel GR, Pederson T: Transcription of a human U6 small nuclear RNA gene In vivo withstands deletion of intragenic sequences but not of an upstream TATATA box. Nucleic Acids Res (1989) 17:7371-7379.
4. Met gene. Nucleic Acids Res (1984) 12:1101-1115.
5. Pruzan R, Flint SJ: Transcription of adenovirus RNA polymerase III genes. Curr Top Microbiol Immunol (1995) 199:201-226.
6. Prislei S, Buonomo SBC, Michienzi A, Bozzoni I: Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes. RNA (1997) 3:677-687.
7. He Y, Huang L: Growth Inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter. Cancer Res (1997) 57:3993-3999.
8. Du Z, Ricordi C, Inverardi L, Podack E, Pastori RL: Efficient ex vivo inhibition of perform and Fas ligand expression by chimeric tRNA-hammerhead ribozymes. Hum Gene Ther (1998) 9:1551-1560.
9. Zhou C, Bahner I, Rossi JJ, Kohn DB: Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition. Antisense Nucleic Acid Drug Dev (1996) 6:17-24.
10. Thompson JD, Ayers DF, Malmstrom TA, McKenzie TL, Ganousis L, Chowrira BM, Couture L, Stinchcomb DT: improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res (1995) 23:2259-2268.
11. Baier G, Coggeshall KM, Baier-Bitterlich G, Giampa L, Telford D, Herbert E, Shih W, Altman A: Construction and Characterization of Ick- and fyn-specific tRNA: Ribozyme chimeras. Mol Immunol (1994) 31:923-932.
12. Duan L, Zhu M, Ozaki I, Zhang H, Wei DL, Pomerantz RJ: Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy. Gene Ther (1997) 4:533-543.
13. Ohkawa J, Yuyama N, Takebe Y, Nishikawa S, Taira K: Importance of independence in ribozyme reactions: Kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus. Proc Natl Acad Sci USA (1993) 90:11302-11306.
14. Ohkawa J, Yuyama N, Takebe Y, Nishikawa S, Homann M, Sczakiel G, Taira K: Multiple site-specific cleavage of HIV RNA by transcribed ribozymes from shotgun-type trimming plasmid. Nucleic Acids Symp Ser (1993) 29:121-122.
15. Yuyama N, Ohkawa J, Koguma T, Shirai M, Taira K: A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5′- and 3′-trimmed frans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester transactivator proteins such as Tat and Rev. Nucleic Acids Res (1994) 22:5060-5067.
16. Yuyama N, Ohkawa J, Inokuchi Y, Shirai M, Sato A, Nishikawa S, Taira K: Construction of a tRNA-embedded-ribozyme trimming plasmid. Biochem Biophys Res Commun (1992) 186:1271-1279.
17. Cotten M, Bimstiel ML: Ribozyme mediated destruction of RNA in vivo. EMBO J (1989) 8:3861-3866.
18. Shore SK, Nabissa PM, Reddy EP: Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oncogene (1993) 8:3183-3188.
19. Gebhard JR, Perry CM, Mahadeviah S, Whitton JL: Use of a non-viral vector to express a chimeric tRNA-ribozyme against lymphocytic choriomeningitis virus: cytoplasmic accumulation of a catalytically competent transcript but minimal antiviral effect Antisense Nucleic Acid Drug Dev (1997) 7:3-11.
20. Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D, Engelke D, Rossi JJ: The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA (1997) 3:75-88.
21. Good PD, Krikos AJ, Li SX, Bertrand E, Lee NS, Giver L, Ellington A, Zaia JA, Rossi JJ, Engelke DR: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther (1997) 4:45-54.
22. Peng H, Callison D, Li P, Burrell CJ: Interference between effector RNAs expressed from conventional dual-function anti-HIV retroviral vectors can be circumvented using dual-effector-cassette retroviral vectors. Hum Gene Ther (1999) 10:449-462.
23. Ilves H, Barske C, Junker U, Böhnlein E, Veres G: Retroviral vectors designed for targeted expression of RNA polymerase Ill-driven transcripts: a comparative study. Gene (1996) 171:203-208.
24. Junker U, Böhnlein E, Veres G: Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy. Gene Ther (1995) 2:639-646.
25. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E: Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell (1990) 63:601-608.
26. Lee SW, Gallardo HF, Gaspar O, Smith C, Gilboa E: Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther (1995) 2:377-384.
27. Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E: Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol (1992) 4:66-74.
28. Lee SW, Gallardo HF, Gilboa E, Smith C: Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J Virol (1994) 68:8254-8264.
29. Peng H, Callison DE, Li P, Burrell CJ: Enhancement or inhibition of HIV-1 replication by intracellular expression of sense or antisense RNA targeted at different intermediates of reverse transcription. AIDS (1997) 11:587-595.
30. Peng H, Callison D, Li P, Burrell C: Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector. Virology (1996) 220:377-389.
31. Chuah MKL, Vandendriessche T, Chang HK, Ensoli B, Morgan RA: Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. Hum Gene Ther (1994) 5:1467-1475.
32. Sullenger BA, Lee TC, Smith CA, Ungers GE, Gilboa E: Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication. Mol Cell Biol (1990) 10:6512-6523.
33. Junker U, Rittner K, Homann M, Bevec D, Böhnlein E, Sczakiel G: Reduction in replication of the human immunodeficiency virus type 1 in human T cell lines by polymerase Ill-driven transcription of chimeric tRNA-antisense RNA genes. Antisense Res Dev(1994) 4:165-172.
34. Kawasaki H, Ohkawa J, Tanishige N, Yoshinari K, Murata T, Yokoyama KK, Taira K: Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase. Nucleic Acids Res (1996) 24:3010-3016.
35. Kawasaki H, Eckner R, Yao TP, Taira K, Chiu R, Livingston DM, Yokoyama KK: Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation Nature (1998) 393:284-289.
36. Westaway SK, Cagnon L, Chang Z, Li S, Li H, Larson GP, Zaia JA, Rossi JJ: Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection. Antisense Nucleic Acid Drug Dev (1998) 8:185-197.
37. Koseki S, Tanabe T, Tani K, Asano S, Shioda T, Nagai Y, Shimada T, Ohkawa J, Taira K: Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J Virol (1999) 73:1868-1877.
38. Kuwabara T, Warashina M, Tanabe T, Tani K, Asano S, Taira K: A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Mol Cell (1998) 2:617-627.
39. Kuwabara T, Warashina M, Nakayama A, Ohkawa J, Taira K: Activities of tRNA-embedded dimeric minizymes. Nucleic Acids Symp Ser (1997) 37:307-308.
40. Kuwabara T, Warashina M, Nakayama A, Ohkawa J, Taira K: tRNAVal-heterodimeric maxizymes with high potential as gene inactivating agents: simultaneous cleavage at two sites in HIV-1 Tat mRNA in cultured cells. Proc Natl Acad Sci USA (1999) 96:1886-1891.
41. Koseki S, Ohkawa J, Yamamoto R, Takebe Y, Taira K: A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase. J Control Release (1998) 53:159-173.
42. Yu M, Ojwang J, Yamada O, Hampel A, Rapapport J, Looney D, Wong-Staal F: A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA (1993) 90:6340-6344.
43. Yamada O, Kraus G, Leavitt MC, Yu M, Wong-Staal F: Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Virology (1994) 205:121-126.
44. Yamada O, Kraus G, Luznik L, Yu M, Wong-Staal F: A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol (1996) 70:1596-1601.
45. Leavitt MC, Yu M, Yamada O, Kraus G, Looney D, Poeschla E, Wong-Staal F: Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther (1994) 5:1115-1120.
46. Yu M, Poeschla E, Yamada O, Degrandis P, Leavitt MC, Heusch M, Yees JK, Wong Staal F, Hampel A: In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology (1995) 206:381-386.
47. Li X, Gervaix A, Kang D, Law P, Spector SA, Ho AD, Wong-Staal F: Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies. Gene Ther (1998) 5:233-239.
48. Yamada O, Yu M, Yee JK, Kraus G, Looney D, Wong-Staal F: Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther (1994) 1:38-45.
49. Heusch M, Kraus G, Johnson P, Wong-Staal F: Intracellular immunization against SIVmac utilizing a hairpin ribozyme. Virology (1996) 216:241-244.
50. Rosenzweig M, Marks DF, Hempel D, Heusch M, Kraus G, Wong-Staal F, Johnson RP: Intracellular immunization of rhesus CD34+ hematopoietic progenitor cells with a hairpin ribozyme protects T cells and macrophages from simian immunodeficiency virus infection. Blood (1997) 90:4822-4831.
51. Gervaix A, Schwarz L, Law P, Ho AD, Looney D, Lane T, Wong-Staal F: Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals. Hum Gene Ther (1997) 8:2229-2238.
52. Gervaix A, Li X, Kraus G, Wong-Staal F: Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol (1997) 71:3048-3053.
53. Westaway SK, Larson GP, Li S, Zaia JA, Rossi JJ: A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly. Nucleic Acids Symp Ser (1995) 33:194-199.
54. Lu Y, Planelles V, Li X, Palaniappan C, Day B, Challita-Eid P, Amado R, Stephens D, Kohn DB, Bakker A, Fay P, Bambara RA, Rosenblatt JD: Inhibition of HIV-1 replication using a mutated tRNALys-3 primer. J Biol Chem (1997) 272:14523-14531.
55. Medina MF, Joshi S: Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes. Nucleic Acids Res (1999) 27:1698-1708.
56. Biasolo MA, Radaelli A, Del Pup L, Franchin E, De Giuli-Morghen C, Palu G: A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection. J Virol (1996) 70:2154-2161.
57. Perriman R, Bruening G, Dennis ES, Peacock WJ: Effective ribozyme delivery in plant cells. Proc Natl Acad Sci USA (1995) 92:6175-6179.
58. Perriman R, de Feyter R: tRNA delivery systems for ribozymes. Methods Mol Biol (1997) 74:393-402.
59. Zhao JJ, Lemke G: Selective disruption of neuregulin-1 function in vertebrate embryos using ribozyme-tRNA transgenes. Development (1998) 125:1899-1907.
60. Lazarev VN, Shmarov MM, Zakhartchouk AN, Yurov GK, Misurina OU, Akopian TA, Grinenko NF, Grodnitskaya NG, Kaverin NV, Naroditsky BS: Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. Antiviral Res (1999) 42:47-57.
61. Zakharchuk AN, Doronin KK, Karpov VA, Krougliak VA, Naroditsky BS: The fowl adenovirus type 1 (CELO) virus-associated RNA-encoding gene: a new ribozyme-expression vector. Gene (1995) 161:189-193.
62. Barcellini-Couget S, Fenard D, Bertrand E, Singer RH, Lefebvre JC, Doglio A: 3′-End modification of the adenoviral VA1 gene affects its expression in human cells: consequences for the design of chimeric VA1 RNA ribozymes. Antisense Nucleic Acid Drug Dev (1998) 8:379-390.
63. Ventura M, Wang P, Franck N, Saragosti S: Ribozyme targeting of HIV-1 LTR. Biochem Biophys Res Commun (1994) 203:889-898.
64. Ventura M, Wang P, Ragot T, Perricaudet M, Saragosti S: Activation of HIV-specific ribozyme activity by self-cleavage. Nucleic Acids Res (1993) 21:3249-3255.
65. Yu M, Leavitt MC, Maruyama M, Yamada O, Young D, Ho AD, Wong-Staal F: Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc Natl Acad Sci USA (1995) 92:699-703.
66. Jennings PA, Molloy PL: Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III. EMBO J (1987) 6:3043-3047.
67. Cagnon L, Cucchiarini M, Lefebvre JC, Doglio A: Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule. J Acquired Immune Defic Syndr Hum Retrovirol (1995) 9:349-358.
68. Beck J, Nassal M: Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res (1995) 23:4954-4962.
69. Xu ZD, Oey L, Mohan S, Kawachi MH, Lee NS, Rossi JJ, Fujita-Yamaguchi Y: Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells. Endocrinology (1999) 140:2134-2144.
70. Browning CM, Cagnon L, Good PD, Rossi J, Engelke DR, Markovitz DM: Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. J Virol (1999) 73:5191-5195.
71. He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, Grandis JR: Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst (1998) 90:1080-1087.
72. Birikh KR, Heaton PA, Eckstein F: The structure, function and application of the hammerhead ribozyme. Eur J Biochem (1997) 245:1-16.
73. Hampel A: The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Prog Nucleic Acid Res Mol Biol (1998) 58:1-39.
74. Wolin SL, Matera AG: The trials and travels of tRNA. Genes Dev (1999) 13:1-10.
75. Arts GJ, Fomerod M, Mattaj IW: Identification of a nuclear export receptor for tRNA. Curr Biol (1998) 8:305-314.
76. Arts GJ, Kuersten S, Romby P, Ehresmann B, Mattaj IW: The role of exportin-t in selective nuclear export of mature tRNAs. EMBO J (1998) 17:7430-7441.
77. Kutay U, Lipowsky G, Izaurralde E, Bischoff FR, Schwarzmaier P, Hartmann E, Görlich D: Identification of a tRNA-specific nuclear export receptor. Mol Cell (1998) 1:359-369.
78. Sullenger BA, Cech TR: Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science (1993) 262:1566-1569.
79. Mak J, Kleiman L: Primer tRNAs for reverse transcription. J Virol (1997) 71:8087-8095.
80. Kuwabara T, Warashina M, Orita M, Koseki S, Ohkawa J, Taira K: Formation of a catalytically active dimer by tRNA(Val)-driven short ribozymes. Nature Biotechnol (1998) 16:961-965.
81. Mathews MB, Shenk T: Adenovirus virus-associated RNA and translation control. J Virol (1991) 65:5657-5662.
82. Pace U, Bockman JM, MacKay BJ, Miller WH Jr, Dmitrovsky E, Goldberg AR: A ribozyme which discriminates in vitro between PML/RAR alpha, the t(15;17)-associated fusion RNA of acute promyelocytic leukemia, and PML and RAR alpha, the transcripts from the nonrearranged alleles. Cancer Res (1994) 54:6365-6369.
83. Kozu T, Sueoka E, Okabe S, Sueoka N, Komori A, Fujiki H: In vitro catalytic activities of DNA/RNA chimeric hammerhead ribozymes against AML1-MTG8 mRNA, a fused gene transcript in acute myeloid leukemia with t(8;21). Biochimie (1996) 78:1067-1073.
84. Kuwabara T, Warashina M, Tanabe T, Tani K, Asano S, Taira K: Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res (1997) 25:3074-3081.
85. Wiechen K, Zimmer C, Dietel M: Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther (1998) 5:45-51.
86. Ozaki I, Zem MA, Liu S, Wei DL, Pomerantz RJ, Duan L: Ribozyme-mediated specific gene replacement of the alpha1-antitrypsin gene in human hepatoma cells. J Hepatol (1999) 31:53-60.
87. Wong-Staal F, Poeschla EM, Looney DJ: A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther (1998) 9:2407-2425.